Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Invested Capital (2016 - 2025)

Historic Invested Capital for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $1.1 billion.

  • Amphastar Pharmaceuticals' Invested Capital rose 457.43% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 457.43%. This contributed to the annual value of $1.1 billion for FY2024, which is 943.47% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Invested Capital is $1.1 billion, which was up 457.43% from $1.1 billion recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Invested Capital high stood at $1.1 billion for Q3 2025, and its period low was $459.4 million during Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Invested Capital averaged around $811.2 million, with its median value being $940.1 million (2023).
  • In the last 5 years, Amphastar Pharmaceuticals' Invested Capital surged by 9176.84% in 2023 and then plummeted by 283.58% in 2024.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Invested Capital stood at $515.1 million in 2021, then rose by 15.89% to $596.9 million in 2022, then skyrocketed by 64.92% to $984.4 million in 2023, then grew by 9.43% to $1.1 billion in 2024, then increased by 4.13% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.